Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer-Reference-Cited by-同舟云学术

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Published:2018-05-23 Issue:18 Volume:24 Page:4380-4387
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Dickler Maura N.,Saura Cristina,Richards Donald A.,Krop Ian E.,Cervantes Andrés,Bedard Philippe L.^ORCID,Patel Manish R.,Pusztai Lajos,Oliveira Mafalda,Cardenas Alison K.,Cui Na,Wilson Timothy R.,Stout Thomas J.,Wei Michael C.,Hsu Jerry Y.,Baselga José

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy;Current Medicinal Chemistry;2024-08-21

2. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond;Critical Reviews in Oncology/Hematology;2024-08

3. Rational Design of Targeted Gold Nanoclusters with High Affinity to Integrin αvβ3 for Combination Cancer Therapy;Bioconjugate Chemistry;2024-07-15

4. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer;Cancer Chemotherapy and Pharmacology;2024-06-27

5. The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models;Biology;2024-06-07